Overview

Allogeneic Transplantation For Severe Osteopetrosis

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to explore what we believe may be a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality. Prior multi-institutional data in past studies found that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we utilize a reduced intensity design of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Alemtuzumab
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine